• 1. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 2. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 5. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Diarylethers
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Diarylethers

Professional Introduction to Compound with CAS No. 181632-57-5 and Product Name: 2-(Pyridin-3-yloxy)pyridin-4-amine

2-(Pyridin-3-yloxy)pyridin-4-amine, identified by the CAS number 181632-57-5, is a significant compound in the field of pharmaceutical chemistry and drug development. This heterocyclic amine derivative has garnered considerable attention due to its unique structural properties and potential applications in medicinal chemistry. The compound features a pyridine core linked through an oxygen atom to another pyridine ring, with an amine functional group at the 4-position of the second pyridine ring. Such a molecular architecture suggests versatile interactions with biological targets, making it a promising candidate for further exploration.

The structural motif of 2-(Pyridin-3-yloxy)pyridin-4-amine is reminiscent of many bioactive molecules that have been investigated for their pharmacological effects. The presence of two pyridine rings enhances its ability to engage with proteins and enzymes through hydrogen bonding and π-stacking interactions. These characteristics are particularly relevant in the design of small-molecule inhibitors and modulators. Recent advancements in computational chemistry have enabled the prediction of binding affinities and pharmacokinetic profiles, which are crucial for drug discovery efforts.

In the context of contemporary research, 2-(Pyridin-3-yloxy)pyridin-4-amine has been explored as a scaffold for developing novel therapeutic agents. Its dual functionality allows for modifications at both the 3-hydroxy group and the 4-amino group, providing chemists with ample opportunities to tailor its properties for specific biological targets. For instance, derivatives of this compound have been investigated for their potential in modulating enzyme activity, particularly in pathways associated with inflammation and cancer.

One of the most compelling aspects of 2-(Pyridin-3-yloxy)pyridin-4-amine is its structural similarity to known pharmacophores. This similarity suggests that it may exhibit analogous biological activities, but with the potential for improved efficacy or reduced side effects. In vitro studies have begun to elucidate its interactions with various proteins, providing insights into its mechanism of action. These studies often employ techniques such as nuclear magnetic resonance (NMR) spectroscopy, X-ray crystallography, and surface plasmon resonance (SPR) to characterize binding events at a molecular level.

The pharmaceutical industry has long been interested in pyridine derivatives due to their broad spectrum of biological activities. 2-(Pyridin-3-yloxy)pyridin-4-amine represents a novel addition to this class of compounds, offering a unique combination of structural features that may confer advantages over existing agents. Its potential applications span multiple therapeutic areas, including central nervous system disorders, cardiovascular diseases, and metabolic syndromes. The compound’s ability to cross the blood-brain barrier is particularly noteworthy, as many CNS drugs require this capability for efficacy.

Recent research has also highlighted the importance of solvent effects on the behavior of 2-(Pyridin-3-yloxy)pyridin-4-amine. Studies have demonstrated that subtle changes in pH or solvent composition can significantly influence its reactivity and binding affinity. This underscores the need for careful optimization during drug development processes. Techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS) are employed to monitor purity and stability under various conditions.

The synthesis of 2-(Pyridin-3-yloxy)pyridin-4-amine presents both challenges and opportunities for synthetic chemists. The construction of the pyridine-pyridine linkage requires precise control over reaction conditions to avoid unwanted side products. Advances in catalytic methods have made it possible to achieve these transformations more efficiently, reducing both cost and environmental impact. Green chemistry principles are increasingly being applied to improve sustainability in pharmaceutical synthesis.

As our understanding of biological systems grows, so does the demand for targeted therapies. 2-(Pyridin-3-yloxy)pyridin-4-amine fits into this broader trend by offering a versatile scaffold for drug discovery. Its potential lies not only in its intrinsic properties but also in its ability to be modified into more complex structures through combinatorial chemistry approaches. Libraries derived from this compound could be screened against large panels of biological targets to identify lead compounds for further development.

The regulatory landscape for new drugs continues to evolve, emphasizing safety and efficacy through rigorous testing protocols. 2-(Pyridin-3-yloxy)pyridin-4-amine must undergo comprehensive preclinical studies before it can be considered for human trials. These studies will assess its toxicity profile, pharmacokinetic behavior, and interaction with other molecules. The results will guide decisions on whether to proceed with clinical development or explore alternative derivatives.

In conclusion,2-(Pyridin-3-yloxy)pyridin-4-amineseems poised to make significant contributions to pharmaceutical research due to its unique structure and promising biological properties. Ongoing studies continue to uncover new aspects of its behavior, reinforcing its position as a valuable candidate for drug development efforts worldwide.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)